Therapeutics: Methylenetetrahydrofolate dehydrogenase 2 (MTHFD2); MLL-AF9 fusion oncogene

Cancer

INDICATION: Acute myelogenous leukemia (AML)

Cell culture and mouse studies suggest inhibiting MTHFD2

Read the full 125 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE